Abstract
Cisplatin remains the most efficient drug in head and neck cancer (HNC). When added to radiation therapy cisplatin increases the acute and late toxicities, with nephrotoxicity being a drug-specific and dose limiting adverse effect. Volume expansion with saline diuresis is the only demonstrated preventive and therapeutic intervention. Current practice is to administer high-dose cisplatin as outpatient. There are no formulated protocols for prevention of renal toxicity in this setting. We developed our own protocol for the outpatient administration of high-dose cisplatin (op-HD-cis) concurrent with radiation therapy in patients (pts) with HNC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology, Biology, Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
